HK1180720A1 - Stabilized alpha galactosidase and uses thereof - Google Patents

Stabilized alpha galactosidase and uses thereof

Info

Publication number
HK1180720A1
HK1180720A1 HK13107909.0A HK13107909A HK1180720A1 HK 1180720 A1 HK1180720 A1 HK 1180720A1 HK 13107909 A HK13107909 A HK 13107909A HK 1180720 A1 HK1180720 A1 HK 1180720A1
Authority
HK
Hong Kong
Prior art keywords
alpha galactosidase
stabilized alpha
stabilized
galactosidase
alpha
Prior art date
Application number
HK13107909.0A
Other languages
English (en)
Chinese (zh)
Inventor
Avidor Shulman
Ilya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of HK1180720A1 publication Critical patent/HK1180720A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
HK13107909.0A 2010-03-02 2013-07-05 Stabilized alpha galactosidase and uses thereof HK1180720A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (1)

Publication Number Publication Date
HK1180720A1 true HK1180720A1 (en) 2013-10-25

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13107909.0A HK1180720A1 (en) 2010-03-02 2013-07-05 Stabilized alpha galactosidase and uses thereof

Country Status (24)

Country Link
EP (3) EP2542675B1 (pl)
JP (2) JP5758920B2 (pl)
KR (1) KR101928403B1 (pl)
CN (1) CN102933707B (pl)
AU (1) AU2011222452B2 (pl)
BR (2) BR112012022029B1 (pl)
CA (1) CA2791461C (pl)
DK (1) DK2865751T3 (pl)
ES (2) ES2606532T3 (pl)
FI (1) FIC20230032I1 (pl)
HK (1) HK1180720A1 (pl)
HR (1) HRP20200428T1 (pl)
HU (2) HUE030959T2 (pl)
IL (2) IL221741A (pl)
IN (1) IN2012MN02262A (pl)
NL (1) NL301249I2 (pl)
NO (1) NO2023041I1 (pl)
NZ (2) NZ602317A (pl)
PL (1) PL2865751T3 (pl)
RU (1) RU2604795C2 (pl)
SG (2) SG183558A1 (pl)
SI (1) SI2865751T1 (pl)
WO (1) WO2011107990A1 (pl)
ZA (1) ZA201206725B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
AU2011222452B2 (en) * 2010-03-02 2015-09-03 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US9732333B2 (en) * 2011-01-20 2017-08-15 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
FI3237621T3 (fi) * 2014-12-22 2023-06-01 Codexis Inc Ihmisen alfa-galaktosidaasivariantteja
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
ES2899783T3 (es) 2015-03-17 2022-03-14 eleva GmbH Proteínas lisosómicas glucosiladas, método de producción y utilizaciones
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20190103320A (ko) * 2017-01-05 2019-09-04 프로탈릭스 리미티드 안정화된 알파-갈락토시다제를 이용하는 파브리의 치료를 위한 치료적 요법
EP4321212A2 (en) * 2017-06-07 2024-02-14 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
AU2019403323A1 (en) 2018-12-20 2021-07-01 Codexis, Inc. Human alpha-galactosidase variants
US20240002814A1 (en) 2020-11-03 2024-01-04 Protalix Ltd. Modified uricase and uses thereof
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287A (zh) * 2022-11-24 2023-06-13 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
WO1999012959A1 (en) * 1997-09-05 1999-03-18 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
RU2278680C2 (ru) * 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
EP1172372B1 (en) * 1999-04-02 2005-08-31 Ajinomoto Co., Inc. Process for producing subunit peptide origintaing in polymer protein
EP1523548B1 (en) 2002-05-15 2009-12-30 Agricultural Research Organization Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
EP1877099B1 (en) * 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
BRPI0618583A2 (pt) * 2005-11-18 2011-09-06 Tokyo Metropolitan Org Med Res enzima altamente funcional tendo especifidade ao substrato modificada
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
AU2011222452B2 (en) * 2010-03-02 2015-09-03 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof

Also Published As

Publication number Publication date
NL301249I1 (pl) 2023-11-08
IL221741A (en) 2017-07-31
JP5871999B2 (ja) 2016-03-01
ES2708843T3 (es) 2019-04-11
CA2791461A1 (en) 2011-09-09
FIC20230032I1 (fi) 2023-11-02
PL2865751T3 (pl) 2017-03-31
BR112012022029A2 (pt) 2021-05-18
RU2604795C2 (ru) 2016-12-10
AU2011222452B2 (en) 2015-09-03
IN2012MN02262A (pl) 2015-06-12
SG10201502609QA (en) 2015-05-28
JP2013520986A (ja) 2013-06-10
WO2011107990A1 (en) 2011-09-09
IL253249B (en) 2020-08-31
HUS2300038I1 (hu) 2023-11-28
NL301249I2 (nl) 2023-12-14
EP2865751A1 (en) 2015-04-29
EP2542675B1 (en) 2014-12-17
NO2023041I1 (no) 2023-11-01
CN102933707A (zh) 2013-02-13
HRP20200428T1 (hr) 2020-06-12
EP2542675A1 (en) 2013-01-09
CA2791461C (en) 2019-10-22
ZA201206725B (en) 2013-06-26
JP5758920B2 (ja) 2015-08-05
AU2011222452A1 (en) 2012-09-27
SI2865751T1 (sl) 2017-01-31
NZ623294A (en) 2015-10-30
HUE030959T2 (en) 2017-06-28
KR20130056216A (ko) 2013-05-29
EP2865751B1 (en) 2016-09-14
IL253249A (en) 2019-08-29
EP3088514A1 (en) 2016-11-02
EP3088514B1 (en) 2018-11-28
KR101928403B1 (ko) 2018-12-14
ES2606532T3 (es) 2017-03-24
BR122014021216A2 (pt) 2021-06-01
DK2865751T3 (en) 2017-01-09
CN102933707B (zh) 2015-09-30
JP2014237694A (ja) 2014-12-18
NZ602317A (en) 2014-04-30
RU2012141651A (ru) 2014-04-10
BR112012022029B1 (pt) 2022-10-11
SG183558A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
SG10201505475XA (en) Romidepsin solid forms and uses thereof
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
EP2582836A4 (en) PRPK-TPRKB MODULATORS AND ITS APPLICATIONS
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
PL2627668T3 (pl) Peptydy i ich zastosowanie
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2598631A4 (en) RECOMBINANT BACTERIUM AND ITS USE
EP2619580A4 (en) SOLUTION MICROARRAYS AND USES THEREOF
GB201017093D0 (en) Biomarkers and uses thereof
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201020268D0 (en) Composition and uses
GB201019361D0 (en) Biosensor and uses thereof
GB201014319D0 (en) Compounds and uses thereof